Neurocrine Biosciences (NBIX) Shares are Down -6.12%

Neurocrine Biosciences (NBIX) has risen sharply, recording gains of 2.43% in the past 4 weeks. However, the stock has corrected -6.12% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.98% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.62% and the 50-Day Moving Average is 0.39%.The 200 Day SMA reached 10.74%


Neurocrine Biosciences (NASDAQ:NBIX): After opening at $50.49, the stock dipped to an intraday low of $50 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $51.76 and the buying power remained strong till the end. The stock closed at $50.64 for the day, a gain of 0.62% for the day session. The total traded volume was 1,040,583. The stocks close on the previous trading day was $50.64.

Neurocrine Biosciences (NBIX) : 9 investment research analysts covering Neurocrine Biosciences (NBIX) have an average price target of $69.44 for the near short term. The highest target price given by the Brokerage Firm to the stock is $96 and the lowest target is $57 for the short term. Analysts expect the variance to be within $12.32 of the average price.

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.